- Home
- FTHM vs COCH Comparison
FTHM vs COCH Comparison
Compare FTHM & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FTHM | COCH |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 51.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FTHM | COCH |
|---|---|---|
| Price | $0.72 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 134.4K | 120.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | $241,000.00 |
| Revenue This Year | $11.67 | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | 7.11 |
| 52 Week Low | $0.40 | $0.36 |
| 52 Week High | $3.37 | $1.89 |
Technical Indicators
Market Signals| Indicator | FTHM | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 55.30 |
| Support Level | $0.70 | $0.63 |
| Resistance Level | $0.92 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.67 | 56.12 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.